
Opinion|Videos|March 27, 2024
The Role of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer
The Oncology Brothers are joined by Thomas Powles, MBBS, MRCP, MD, to discuss the role of enfortumab vedotin plus pembrolizumab in the bladder cancer treatment landscape.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5









































